Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Metastatic Triple Negative Breast Cancer
NCT03577743Phase 2Completed
- Sponsor
- Assiut University
- Start
- Jul 2018
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in triple-negative breast cancer (TNBC), sponsored by Assiut University. Primary endpoint: Progression Free Survival at 6 months. Started Jul 2018; status: completed.
02
Drugs
bevacizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03577743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03577743.